Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data VACCINEX, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
0.09
0.72
0.52
0.63
0.9
0.28
0.57
0.6
Cost of revenue
0.16
1.03
0.2
0
Gross profit
-0.07
-0.31
0.32
0.62
Research and development
16.6
22.4
25.7
21.5
17.2
14
16.6
12.5
General and administrative
4.48
4.62
6.67
7.41
6.23
6.2
6.88
6.79
Operating income
-21.1
-27.3
-32
-28.3
-22.5
-19.9
-22.9
-18.7
Interest expense
1.36
0.39
0.49
0.81
0
0
0
Other non-operating income
-0.04
0.17
0.15
-0.03
0.04
0.09
0.91
0.04
Pre-tax income
-18.8
-29.5
-31.9
-28.9
-22.4
-19.8
-20.3
-18.6
Income tax
0
0
0
0
0
0
0
0
Net income to minority interests
-0.04
0
0
0
0
Net income
-18.7
-29.5
-31.9
-28.9
-22.4
-19.8
-20.3
-18.6
EBITDA
-20.9
-27.1
-31.8
-28
-22.3
-19.7
-22.8
-18.6
EPS, basic
-4,151.00
-1,179.00
-515.28
-321.27
-162.72
-98.05
-43.68
-8.88
EPS, diluted
-4,151.00
-1,179.00
-515.28
-321.27
-162.72
-98.05
-43.68
-8.88
Shares, basic (weighted)
0.01
0.03
0.06
0.09
0.14
0.2
0.46
2.1
Shares, diluted (weighted)
0.01
0.03
0.06
0.09
0.14
0.2
0.46
2.1
Balance sheet
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
4.18
5.62
2.78
10.6
8.59
6.39
1.54
1.11
Short-term investments
14.1
0
Receivables
0.12
0.64
0.9
0.16
0.18
0.96
0.84
Other current assets
0.68
1.06
0.34
0.53
0.82
0.91
0.85
0.59
Total current assets
4.97
21.4
4.01
11.3
9.41
7.48
3.35
2.53
Property, plant and equipment
0.6
0.6
0.59
0.42
0.3
0.19
0.14
0.07
Lease right-of-use assets
0.14
0.31
0.15
0
Total assets
5.58
22
4.6
11.7
9.84
7.98
3.63
2.6
Accounts payable
1.91
2.32
3.21
3.17
1.06
1.52
2.04
3.96
Accrued liabilities
1.96
4.36
3.67
1.94
0.98
0.78
1.24
1.1
Deferred revenue
0.3
0.06
0
Short-term debt
0.07
0.07
0.08
0.03
Total current liabilities
4.17
6.69
6.88
13.2
2.26
2.54
5.92
5.08
Long-term debt
1.13
0.18
0.1
0.03
0
Lease liabilities
0.15
Total liabilities
7.35
6.69
6.88
14.3
2.43
2.78
5.94
5.08
Total debt
1.13
0.25
0.18
0.1
0.03
Paid-in capital
54.1
208
222
251
307
325
338
354
Retained earnings
-187
-217
-249
-277
-300
-320
-340
-359
Treasury stock
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Shareholders' equity
-125
-8.62
-26.2
-26.6
7.41
Minority interests
12
24
24
24
Total equity
-113
15.3
-2.27
-2.61
7.41
5.19
-2.31
-2.49
Total liabilities and equity
5.58
22
4.6
11.7
9.84
7.98
3.63
2.6
Shares outstanding
0.01
0.06
0.07
0.11
0.15
0.24
0.89
2.68
Cash flow statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-18.8
-29.5
-31.9
-28.9
-22.4
-19.8
-20.3
-18.6
Depreciation and amortization
0.21
0.22
0.25
0.31
0.17
0.21
0.12
0.09
Stock-based compensation
0.32
0.18
0.45
0.73
0.54
0.55
0.47
0.34
Change in receivables
-0.01
-0.52
-0.26
0.74
0.16
-0.18
-0.79
0.12
Change in payables
-0.56
0.42
0.73
0.12
-2.11
0.46
0.52
1.91
Cash from operations
-21.4
-25.3
-30.7
-28.6
-25.3
-19.1
-21.4
-16.2
Capital expenditures
-0.07
-0.24
-0.08
-0.29
-0.03
-0.1
-0.07
-0.02
Purchases of investments
-20.8
Sales and maturities of investments
6.75
14.2
Cash from investing
-0.07
-14.2
14.1
-0.29
-0.03
-0.1
-0.07
-0.02
Debt issued
1.13
Debt repaid
-0.01
-0.08
-0.07
-0.08
Stock issued
0.02
0.01
17
32.8
3.56
1.28
Cash from financing
24
41
13.8
36.8
23.3
17
16.6
15.8
Net change in cash
2.52
1.44
-2.84
7.82
-2.01
-2.2
-4.86
-0.43
Free cash flow
-21.5
-25.5
-30.8
-28.9
-25.3
-19.2
-21.4
-16.2
Interest paid
0.01
0.28
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. Valuation uses the share price of $1.00 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-3,117.0%
Operating income / revenue.
EBITDA margin
-3,102.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-3,100.0%
Pre-tax income / revenue.
Net margin
-3,100.0%
Net income / revenue.
FCF margin
-2,697.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2,693.0%
Cash from operations / revenue.
Return on assets (ROA)
-598.5%
Net income / average total assets.
R&D / revenue
2,087.0%
Research and development expense / revenue.
Stock-based pay / revenue
56.7%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
3.7%
Capital expenditures / revenue.
D&A / revenue
15.6%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
5.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-12.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
2.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-28.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-35.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-10.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
352.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
147.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
102.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.50x
Current assets / current liabilities.
Quick ratio
0.38x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.22x
(Cash + short-term investments) / current liabilities.
Debt / assets
1.0%
Total debt / total assets.
Liabilities / assets
195.8%
Total liabilities / total assets.
Net debt
-$1.1M
Total debt - cash - short-term investments. Negative means more cash than debt.
Interest coverage
-9,367x
Operating income / interest expense.
Working capital
-$2.6M
Current assets - current liabilities.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.19x
Revenue / average total assets.
Fixed asset turnover
5.98x
Revenue / average property, plant and equipment.
Receivables turnover
0.67x
Revenue / average receivables.
Days sales outstanding
546 days
365 x average receivables / revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$8.88
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$8.88
Net income per basic share, as reported (split-adjusted).
Market cap + total debt - cash - short-term investments.
P/S
4.45x
Market cap / revenue.
EV/Sales
2.65x
Enterprise value / revenue.
FCF yield
-605.5%
Free cash flow / market cap.
Earnings yield
-696.2%
Net income / market cap (the inverse of P/E).
What was VACCINEX, INC.'s revenue in fiscal 2024?
VACCINEX, INC. reported revenue of $601.0K for fiscal 2024, 5.4% higher than the year before.
Was VACCINEX, INC. profitable in fiscal 2024?
No. It reported a net loss of $18.6M.
How much free cash flow did VACCINEX, INC. generate in fiscal 2024?
Cash from operations of $16.2M minus capital expenditures of $22.0K left free cash flow of -$16.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.